ASTRAZENECA PLC Form SC 13G/A February 12, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 5) *

AstraZeneca plc (Name of Issuer)

American Depositary Shares, representing Ordinary Shares (Title of Class of Securities)

046353108 (CUSIP Number)

December 29, 2006 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [X] Rule 13d-1(b)
- [] Rule 13d-1(c)
- [] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP: 046353108 Page 1 of 5

1	I.R.S.	IDEN Rese	PORTING PERSONS FIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) earch and Management Company	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			(a)
3	SEC USE ONLY			(b)
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
		5	SOLE VOTING POWER	
			52,413,840	
NUMBER OF SHARES BENEFICIALL Y OWNED BY EACH REPORTING PERSON WITH:		6 7	SHARED VOTING POWER NONE SOLE DISPOSITIVE POWER	
			89,997,840	
VV -	L 111•	8	SHARED DISPOSITIVE POWER	
			NONE	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	89,997,	840	Beneficial ownership disclaimed pursuant to Rul	e 13d-4
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHAR (SEE INSTRUCTIONS)			SHARES
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	5.9%			
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)			

ΙA

CUSIP: 046353108 Page 2 of 5

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Schedule 13G Under the Securities Exchange Act of 1934

Amendment No. 5

- Item 1(a) Name of Issuer:
 AstraZeneca plc

- Item 2(b) Address of Principal Business Office or, if none,
 Residence:
 333 South Hope Street
 Los Angeles, CA 90071
- Item 2(c) Citizenship: N/A
- Item 2(d) Title of Class of Securities:
 American Depositary Shares, representing Ordinary Shares
- Item 3 If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
 - (d) [X] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
 - (e) [X] An investment adviser in accordance with section 240.13d-1 (b) (1) (ii) (E).

Item 4 Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

See page 2

- (a) Amount beneficially owned:
- (b) Percent of class:
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:

- (ii) Shared power to vote or to direct the vote:
- (iii) Sole power to dispose or to direct the disposition of:
- (iv) Shared power to dispose or to direct the disposition of:

CUSIP: 046353108 Page 3 of 5

Capital Research and Management Company, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 is deemed to be the beneficial owner of 89,997,840 shares or 5.9% of the 1,531,920,702 shares of American Depositary Shares, representing Ordinary Shares believed to be outstanding as a result of acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940.

Shares reported by Capital Research and Management Company include 26,804,650 American Depositary Shares, representing 26,804,650 Ordinary Shares.

- Item 5 Ownership of Five Percent or Less of a Class. If this
 statement is being filed to report the fact that as of the date
 hereof the reporting person has ceased to be the beneficial
 owner of more than five percent of the class of securities,
 check the following: []
- Item 6 Ownership of More than Five Percent on Behalf of Another Person: N/A
- Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.: N/A
- Item 8 Identification and Classification of Members of the Group: $\ensuremath{\mathrm{N/A}}$
- Item 9 Notice of Dissolution of Group: N/A
- Item 10 Certification

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 6, 2007

Signature: *Paul G. Haaga, Jr.

Name/Title: Paul G. Haaga, Jr., Executive Vice

President

Capital Research and Management Company

CUSIP: 046353108 Page 4 of 5

*By /s/ James P. Ryan James P. Ryan Attorney-in-fact

Signed pursuant to a Power of Attorney dated November 14, 2006 included as an Exhibit to Schedule 13F filed with the Securities and Exchange Commission by Capital Research and Management Company on November 14, 2006.

CUSIP: 046353108 Page 5 of 5